1921
Volume 96, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract

The U.S. Congress created the priority review voucher program in 2007 to encourage development of drugs for neglected diseases. Under the voucher program, the developer of a drug for a neglected or rare pediatric disease that is approved by the U.S. Food and Drug Administration receives a bonus priority review voucher for another drug. As of 2016, four vouchers have sold for an average price of $200 million. Recent experience with the voucher program indicates strengths and weaknesses of the program, as well as a need for legislative changes.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.16-0600
2017-01-11
2017-09-21
Loading full text...

Full text loading...

/deliver/fulltext/14761645/96/1/14.html?itemId=/content/journals/10.4269/ajtmh.16-0600&mimeType=html&fmt=ahah

References

  1. Ridley DB, Grabowski HG, Moe JL, , 2006. Developing drugs for developing countries. Health Aff 25: 313324.[Crossref]
  2. Ridley DB, Régnier SA, , 2016. The commercial market for priority review vouchers. Health Aff 35: 776783.[Crossref]
  3. Hensley S, , 2015. Price Rises for Ticket to a Quicker Drug Review by FDA: National Public Radio. Available at: http://www.npr.org/sections/health-shots/2015/08/19/432887081/price-rises-for-ticket-to-a-quicker-drug-review-by-fda. Accessed August 21, 2015.
  4. Berman J, Radhakrishna T, , 2017. The tropical disease priority review voucher: a game-changer for tropical disease products. Am J Trop Med Hyg 96: 1113.
  5. Adams CP, Brantner VV, , 2006. Estimating the cost of new drug development: is it really $802 million? Health Aff 25: 420428.[Crossref]
  6. Ridley DB, , 2015. The Regulatory Burden of the Priority Review Voucher Program. Health Affairs Blog. Available at: http://healthaffairs.org/blog/2015/10/28/the-regulatory-burden-of-the-priority-review-voucher-program/. Accessed July 7, 2016.
  7. Kesselheim AS, , 2009. Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development. Clin Pharmacol Ther 85: 573575.[Crossref]
  8. Kesselheim AS, Maggs LR, Sarpatwari A, , 2015. Experience with the priority review voucher program for drug development. JAMA 314: 16871688.[Crossref]
  9. Berndt ER, Glennerster R, Kremer MR, Lee J, Levine R, Weizsäcker G, Williams H, , 2007. Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness. Health Econ 16: 491511.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.16-0600
Loading
  • Received : 21 Jul 2016
  • Accepted : 01 Aug 2016

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error